Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Safety and Efficacy of Rifalazil (25 Milligram) Compared With Azithromycin (1 Gram) for the Treatment of Uncomplicated Genital Chlamydia Trachomatis Infection in Women

NCT01631201 is registered in ClinicalTrials.gov with ActivBiotics Pharma, LLC as lead sponsor.

NCT NCT01631201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01631201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Safety and Efficacy of Rifalazil (25 Milligram) Compared With Azithromycin (1 Gram) for the Treatment of Uncomplicated Genital Chlamydia Trachomatis Infection in Women
Lead sponsor
ActivBiotics Pharma, LLC
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
April 30, 2013
Enrollment
82 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chlamydia trachomatis infection